AstraZeneca Jan 25 2025 AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across England and Wales. Tagrisso (osimertinib) received a positive recommendation from NICE for NHS use as an adjuvant treatment option after complete tumor resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor (